Introduction

Interest in combining pharmacological agents with psychological therapies has accelerated in recent years. Cannabidiol (CBD) is among the compounds most discussed in the context of anxiety and ‘‘pharmacologically‑assisted psychotherapy’’. Between 2019 and 2026 a number of trials and reviews have helped clarify what the evidence does—and does not—support. This article summarises the latest randomised controlled trials (RCTs) and related work, explains why findings are mixed, and outlines practical implications for UK therapists, patients and the evolving policy environment.

What the latest RCTs actually found

One of the most important multi‑centre RCTs (Netherlands) tested a 300 mg oral CBD dose given immediately before eight therapist‑assisted exposure sessions in patients diagnosed with either social anxiety disorder or panic disorder with agoraphobia. The study reported no improvement in primary treatment outcomes versus placebo across the course of therapy. Adverse effects were reported at similar rates in both the CBD and placebo groups, suggesting short‑term tolerability but no added clinical benefit in that specific trial context.

These findings fit into a broader pattern. Earlier laboratory studies using single doses commonly between 400–600 mg showed acute reductions in experimentally induced public‑speaking or social anxiety in tightly controlled settings. But when those acute effects were pooled or examined in longer‑term clinical contexts, consistent clinical benefit has not emerged.

Why results are inconsistent

• Heterogeneous dosing and formulations: Trials use a wide variety of formats—single high oral doses, repeated dosing regimens (often 150–600 mg), sublingual tinctures, capsules or other preparations—making direct comparison difficult.
• Timing relative to therapy: Some studies administer CBD acutely before a lab stressor; others combine it repeatedly with therapy sessions. The pharmacokinetic and contextual differences can alter effects.
• Sample and outcome differences: Many early trials were small, used healthy volunteers or analogue tasks rather than patients with diagnosed anxiety disorders, and relied on short‑term outcome measures.
• Preclinical complexity: Animal and cellular studies point to multiple mechanisms of action (5‑HT1A receptor modulation, CB1/CB2 pathways, TRP channels) and a potential biphasic dose–response—meaning low and high doses could produce different, even opposite, effects.

What systematic reviews and UK analyses say

Systematic reviews and UK‑based analyses consistently emphasise a notable gap: a near complete absence of long‑term randomised trials in people diagnosed with anxiety disorders. In practice this means clinicians who wish to explore CBD as an adjunct must rely on small RCTs, single‑dose experimental studies and observational evidence—none of which provide a definitive evidence base for routine use alongside CBT or exposure therapy.

Safety and tolerability considerations

Across recent trials the short‑term side‑effect profile of CBD appears similar to placebo for many people, as shown by the exposure‑therapy RCT in which adverse effects did not differ meaningfully by group. That said, trials differ in population, dose and monitoring, and long‑term safety data in clinical populations remain limited. Given pharmacodynamic complexity, clinicians should be mindful of drug interactions and individual patient factors.

Practical implications for UK therapists and patients

• Evidence‑based caution: Given current RCT results, CBD should not be presented as a proven adjunct to CBT or exposure therapy. Therapists should avoid promising improved outcomes based on the existing trials.
• Informed discussion: If patients ask about CBD, explain the current state of evidence—some acute laboratory studies show transient anxiety reductions, but longer‑term, disorder‑level trials have not demonstrated consistent benefit.
• Shared decision‑making: Where patients are using or considering CBD privately, encourage open communication, documented consent and routine monitoring of mood, sleep and any side effects.
• Consider formulations and dose uncertainty: Trials vary widely in dose and delivery. Some patients use sublingual drops or tinctures such as Wylde Natural Cold‑Pressed Drops 1000mg CBD Oil 10ml or higher‑concentration clinician‑oriented products such as CBD Living Tincture 30ml 4500mg 0% THC, while others prefer standardised oral options like CBD Living 5 mg Gel Capsules or microdosed edibles such as Wylde CBD Gummy Bears 30×10mg. Mentioning products does not imply endorsement of efficacy for therapy adjunctive use—these examples illustrate formulation diversity.
• Record keeping and outcome measurement: If CBD is used alongside therapy, therapists should agree measurable goals and timelines and, where appropriate, liaise with the patient’s prescriber or GP.

Implications for NHS guidance and policy

There is growing clinical and patient interest in CBD within the UK—reflected in registries and private prescribers—but the NHS currently lacks formal guidance on CBD‑assisted psychotherapy. Professional bodies have begun to publish frameworks for other pharmacologically‑assisted therapies (for example, psychedelic‑assisted therapy), signalling a broader policy shift toward integrating medicines and psychotherapy where supported by evidence. If CBD is to be considered within such frameworks, high‑quality, long‑term RCTs that define optimal dosing strategies, timing and patient selection will be essential.

Research priorities

• Large, multi‑centre RCTs in clinically diagnosed anxiety disorders with long‑term follow‑up.
• Trials that systematically compare dosing regimens, formulations and timing relative to exposure sessions to address the biphasic and pharmacokinetic uncertainties.
• Mechanistic studies in people to better link preclinical pathways (5‑HT1A, CB1/CB2, TRP channels) with clinical outcomes.

Conclusion

The most robust recent RCTs do not support routine use of CBD as a proven adjunct to CBT or exposure therapy for anxiety disorders. Earlier single‑dose laboratory studies show promise for acute anxiolytic effects in controlled settings, but pooled and longer‑term data remain inconsistent. For UK therapists and patients this means cautious, transparent conversations and careful monitoring where CBD is already being used. On a policy level, the absence of long‑term RCT evidence leaves the NHS without a clear basis for formal guidance; further high‑quality research and agreed frameworks will be needed before CBD can be responsibly integrated into standard psychotherapeutic practice.